Astrazeneca And Stroke Patients: What's The Verdict?

AstraZeneca's Brilinta (ticagrelor) has been approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA). The approval was based on the Phase III THALES trial, which showed that aspirin combined with 90 mg of Brilinta significantly reduced the rate of stroke and death compared to aspirin alone. This combination treatment is especially beneficial within the first 30 days after an acute ischemic stroke or high-risk TIA, when the risk of a recurrent stroke is highest. Brilinta is an oral antiplatelet medication that inhibits platelet activation and helps prevent blood clots, making it a valuable option for stroke patients to lower their risk of subsequent strokes.

AstraZeneca's Brilinta is approved to reduce the risk of stroke in patients with acute ischemic stroke

In 2020, AstraZeneca's Brilinta was approved by the US Food and Drug Administration (FDA) to reduce the risk of stroke in patients with acute ischemic stroke. This approval was based on positive results from the THALES Phase III trial, which showed that Brilinta, in combination with aspirin, significantly reduced the rate of stroke and death compared to aspirin alone in patients with acute ischemic stroke.

Brilinta (ticagrelor) is an oral, reversible, direct-acting P2Y12 receptor antagonist that inhibits platelet activation. It helps to stop platelets from sticking together and forming clots, thereby reducing the risk of stroke. The THALES trial demonstrated that taking Brilinta 90mg twice daily with daily aspirin for 30 days reduced the rate of stroke and death by 17% compared to aspirin alone in patients with acute ischemic stroke. This reduction was statistically significant and clinically meaningful.

The risk of severe bleeding events was slightly higher in patients receiving aspirin plus Brilinta (0.5%) compared to aspirin alone (0.1%). However, the results were consistent with the known safety profile of Brilinta. It is important to note that Brilinta can cause serious side effects, including bleeding, shortness of breath, slow or irregular heartbeat, and irregular breathing. Patients should seek medical attention if they experience any signs or symptoms of bleeding while taking Brilinta.

Brilinta is now approved in the US to reduce the risk of stroke in patients with acute ischemic stroke, expanding its use beyond cardiovascular disease. This approval provides a new treatment option for patients with acute ischemic stroke, helping to reduce their risk of recurrent stroke and potentially improving their long-term outcomes.

Brilinta is an oral, reversible, direct-acting P2Y12 receptor antagonist

Brilinta (ticagrelor) is a prescription medicine for people who have had a heart attack or severe chest pain due to their heart not getting enough oxygen. It is used to lower the chance of having or dying from a heart attack or stroke. However, Brilinta can also cause bleeding that can be serious and sometimes lead to death.

The rapid on/off receptor kinetics of Brilinta indicate that its inhibitory effect closely reflects levels of drug exposure. It has a rapid and reversible concentration-dependent inhibitory effect on the P2Y12 receptor and appears to offer a wider separation between antithrombotic effects and bleeding time in preclinical models.

Brilinta is a prescription medicine for adults used to:

• Decrease the risk of death, heart attack, and stroke in people with a blockage of blood flow to the heart (acute coronary syndrome or ACS) or a history of a heart attack. Brilinta can also decrease the risk of blood clots in stents in people who have received stents for the treatment of ACS.
• Decrease the risk of a first heart attack or stroke in people who have a condition where the blood flow to the heart is decreased (coronary artery disease or CAD) and are at high risk for having a heart attack or stroke.
• Decrease the risk of stroke in people who are having a stroke (acute ischemic stroke) or temporary stroke-like symptoms, known as a mini-stroke or transient ischemic attack.

Brilinta is used to lower the risk of stroke for patients with a mini-stroke (TIA)

Brilinta is a prescription medicine for adults used to lower the risk of stroke in patients with a mini-stroke (transient ischemic attack, or TIA). It is a type of medicine known as an oral antiplatelet (OAP) that helps stop platelets from sticking together and forming a clot.

In a major clinical study, Brilinta was proven to be more effective than aspirin alone in reducing the risk of another stroke within the first 30 days after an acute ischemic stroke or high-risk TIA (mini-stroke). The study, known as the THALES trial, involved more than 11,000 patients and showed that aspirin plus Brilinta 90mg used twice daily for 30 days resulted in a statistically significant and clinically meaningful reduction in the risk of stroke and death compared to aspirin alone.

Brilinta is approved in more than 110 countries for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.

It is important to note that Brilinta, like other similar drugs, can cause bleeding that can be serious and sometimes lead to death. While taking Brilinta, patients may bruise and bleed more easily and may be more likely to have nosebleeds. Therefore, it is crucial to consult a doctor before taking Brilinta and to report any signs or symptoms of bleeding to a medical professional.

Brilinta is used to lower the chance of having a stroke or dying from it

Brilinta is a prescription medicine for adults who have had a heart attack or acute ischemic stroke. It is also for those with severe chest pain that occurs when the heart does not receive enough oxygen.

In a major clinical study, Brilinta was proven to be more effective than aspirin alone in reducing the risk of having another stroke within the first 30 days after an acute ischemic stroke or high-risk transient ischemic attack (TIA). The study included over 11,000 patients who took Brilinta 90 mg twice daily for 30 days, along with a daily maintenance dose of aspirin.

It is important to note that Brilinta and similar drugs can cause bleeding that can be serious and sometimes lead to death. While taking Brilinta, patients may bruise and bleed more easily and may be more likely to have nosebleeds.

Brilinta should be taken as prescribed by a doctor, and patients should not stop taking it without consulting their doctor. It is typically taken twice daily along with a daily maintenance dose of aspirin.

Brilinta is used in combination with aspirin to reduce the risk of stroke

Brilinta (ticagrelor) is a prescription medicine used to lower the risk of stroke in patients with acute ischaemic stroke or high-risk transient ischaemic attack (TIA). It is an oral, reversible, direct-acting P2Y12 receptor antagonist that inhibits platelet activation. In other words, it helps to stop platelets from sticking together and forming a clot.

In a major clinical study called the THALES trial, Brilinta was found to be more effective than aspirin alone in reducing the risk of stroke and death in patients with acute ischaemic stroke or TIA. The study involved more than 11,000 patients and showed that Brilinta 90mg used twice daily and taken with daily aspirin for 30 days reduced the rate of stroke and death by 17% compared to aspirin alone. This result was statistically significant and clinically meaningful.

Brilinta is typically used in combination with a daily maintenance dose of aspirin, as instructed by a doctor. It is important to note that patients should not take a dose of aspirin higher than 100 mg daily. Additionally, patients should inform their doctors if they are taking other medicines that contain aspirin.

It is worth noting that Brilinta may cause serious side effects, including bleeding, shortness of breath, slow or irregular heartbeat, and irregular breathing. Patients should inform their doctors if they experience any of these side effects. Furthermore, Brilinta may increase the risk of bleeding, so it is important to consult a doctor before starting this medication.

Frequently asked questions